MGIH
Millennium Group International Holdings Ltd
$1.62
+5.88%
$18.2M
No data for this timeframe.
Vol
Market Cap$18.2M
Cap SizeNano Cap
SEC Reports1
Recent Activity
Jun 22, 2026
earnings_calendar
MGIH Q2 2025 Earnings Scheduled — 2026-06-22
Apr 9, 2026
SEC
Millennium Group International Holdings Ltd's Hong Kong subsidiary secured an unsecured HKD 11.7 million (USD 1.49M) loa
6-K — Impact 4/10
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 22, 2026
earnings_calendar
MGIH Q2 2025 Earnings Scheduled — 2026-06-22
May 16, 2026
Clinical Trial
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
Phase Phase 2 — TERMINATED
Apr 2, 2026
Clinical Trial
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
Phase Phase 2 — COMPLETED